Clearmind Medicine宣布约翰霍普金斯IRB批准推进CMND-100 I/II期临床试验进入后续阶段

美股速递
May 26

Clearmind Medicine, Inc. 宣布,其CMND-100的I/II期临床试验已获得约翰霍普金斯大学机构审查委员会的批准,得以推进至后续研究阶段。这一批准标志着该药物临床开发进程中的一个重要节点,为后续研究铺平了道路。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10